DE60220185D1 - Screening-verfahren für substanzen zur behandlung von diabetes - Google Patents

Screening-verfahren für substanzen zur behandlung von diabetes

Info

Publication number
DE60220185D1
DE60220185D1 DE60220185T DE60220185T DE60220185D1 DE 60220185 D1 DE60220185 D1 DE 60220185D1 DE 60220185 T DE60220185 T DE 60220185T DE 60220185 T DE60220185 T DE 60220185T DE 60220185 D1 DE60220185 D1 DE 60220185D1
Authority
DE
Germany
Prior art keywords
activity
diabetes
pai
substances
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60220185T
Other languages
English (en)
Inventor
Kazuhiko Hanashiro
Yoshikuni Nagamine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Original Assignee
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung filed Critical Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Application granted granted Critical
Publication of DE60220185D1 publication Critical patent/DE60220185D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8121—Serpins
    • G01N2333/8132—Plasminogen activator inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60220185T 2001-12-14 2002-12-13 Screening-verfahren für substanzen zur behandlung von diabetes Expired - Lifetime DE60220185D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130007.8A GB0130007D0 (en) 2001-12-14 2001-12-14 Screening method for agents useful in treating diabetes
PCT/EP2002/014233 WO2003052124A2 (en) 2001-12-14 2002-12-13 Screening method for agents useful in treating diabetes

Publications (1)

Publication Number Publication Date
DE60220185D1 true DE60220185D1 (de) 2007-06-28

Family

ID=9927673

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60220185T Expired - Lifetime DE60220185D1 (de) 2001-12-14 2002-12-13 Screening-verfahren für substanzen zur behandlung von diabetes

Country Status (8)

Country Link
US (1) US20050037956A1 (de)
EP (1) EP1458883B1 (de)
JP (1) JP2005512546A (de)
AT (1) ATE362545T1 (de)
AU (1) AU2002366442A1 (de)
DE (1) DE60220185D1 (de)
GB (1) GB0130007D0 (de)
WO (1) WO2003052124A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7771720B2 (en) * 2007-09-07 2010-08-10 Cisthera, Inc. Humanized PAI-1 antibodies
US7981415B2 (en) * 2007-09-07 2011-07-19 Cisthera, Inc. Humanized PAI-1 antibodies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586453B2 (en) * 2000-04-03 2003-07-01 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1

Also Published As

Publication number Publication date
EP1458883A2 (de) 2004-09-22
ATE362545T1 (de) 2007-06-15
EP1458883B1 (de) 2007-05-16
GB0130007D0 (en) 2002-02-06
WO2003052124A3 (en) 2003-11-06
US20050037956A1 (en) 2005-02-17
AU2002366442A8 (en) 2003-06-30
AU2002366442A1 (en) 2003-06-30
WO2003052124A2 (en) 2003-06-26
JP2005512546A (ja) 2005-05-12

Similar Documents

Publication Publication Date Title
BR9908280A (pt) Inibidores de enzimas de fosfolipase
EE200000522A (et) Fosfolipaas A2 ensüümi inhibiitor, seda sisaldav farmatseutiline kompositsioon ning meetod fosfolipaasensüümi toime pärssimiseks
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
BR0011838B1 (pt) elemento de sela e estrutura de misturador estático.
ATE413386T1 (de) Ppar-gamma modulatoren
ATE310955T1 (de) Zusammensetzungen und verfahren zum nachweis und zur behandlung von mit chemokinrezeptoren verbundenen krankheiten
ATE269295T1 (de) Btk inhibitoren und verfahren zur identifizierung und verwendung
TR200100146T2 (tr) Antidepresan etkiye sahip madde
DE60326259D1 (de) Neue fructosylpeptidoxidase und deren nutzung
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
TR200002877T2 (tr) Sülfonamid türevleri
TR199902751T2 (xx) Proteaz inhibit�rleri.
WO2000034511A3 (de) Peptid screening test zum nachweis von ass
GB9924957D0 (en) Novel treatment
DE69633231D1 (de) Tnf-alpha konvertierendes enzym
ATE226254T1 (de) Reagenz zur behandlung von arthritischen zustaenden
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
AU2001233913A1 (en) Bcmp 84, a protein associated to breast cancer
ITRM20020629A1 (it) Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante.
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE60220185D1 (de) Screening-verfahren für substanzen zur behandlung von diabetes
SE0100684D0 (sv) New subject-matter
ATE443262T1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
WO1999001567A3 (en) Methods and compositions for a deubiquitinating enzyme and variants thereof
NZ514691A (en) Method to type prion proteins

Legal Events

Date Code Title Description
8332 No legal effect for de